参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Basal Cell Skin Cancer Version 1.2019-August 31,2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Abbas M,Kalia S.Trends in non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) in Canada:a descriptive analysis of available data.J Cutan Med Surg 2016, 20:166-175.
4.DePry JL,Vyas R,Lazarus HM,et al.Cutaneous malignant neoplasms in hematopoietic cell transplant recipients:a systematic review.JAMA Dermatol 2015, 151:775-782.
5.Basset-Seguin N,Hauschild A,Grob JJ,et al.Vismodegib in patients with advanced basal cell carcinoma (STEVIE):a pre-planned interim analysis of an international,openlabel trial.Lancet Oncol 2015, 16:729-736.
6.Lesiak A,Sobolewska-Sztychny D,Majak P,et al.Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population.Arch Dermatol Res 2016, 308:39-47.
7.Rashtak S,Dierkhising RA,Kremers WK,et al.Incidence and risk factors for skin cancer following lung transplantation.J Am Acad Dermatol 2015, 72:92-98.
8.Sofen H,Gross KG,Goldberg LH,et al.A phase II,multicenter,open-label,3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.J Am Acad Dermatol 2015, 73:99-105 e101.
9.Krynitz B,Olsson H,Lundh Rozell B,et al.Risk of basal cell carcinoma in Swedish organ transplant recipients:a population-based study.Br J Dermatol 2016, 174:95-103.
10.Balamucki CJ,DeJesus R,Galloway TJ,et al.Impact of radiographic findings on for prognosis skin cancer with perineural invasion.Am J Clin Oncol 2015, 38:248-251.
11.Tauber G,Pavlovsky L,Fenig E,et al.Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.J Am Acad Dermatol 2015, 73:799-801.
12.Danial C,Sarin KY,Oro AE,et al.An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib.Clin Cancer Res 2016, 22:1325-1329.(https://www.daowen.com)
13.Verkouteren JA,Smedinga H,Steyerberg EW, et al.Predicting the risk of a second basal cell carcinoma.J Invest Dermatol 2015, 135:2649-2656.
14.Halkud R,Shenoy AM,Naik SM,et al.Xeroderma pigmentosum:clinicopathological review of the multiple oculocutaneous malignancies and complications.Indian J Surg Oncol 2014, 5:120-124.
15.Asgari MM,Moffet HH,Ray GT, et al.Trends in basal cell carcinoma incidence and identification of high-risk subgroups,1998-2012.JAMA Dermatol 2015, 151:976-981.
16.Savoia P,Deboli T,Previgliano A, et al.Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma.Int J Mol Sci 2015, 16:23300-23317.
17.Park GH,Chang SE,Won CH,et al.Incidence of primary skin cancer after organ transplantation:An 18-year singlecenter experience in Korea.J Am Acad Dermatol 2014, 70:465-472.
18.Rogers HW,Weinstock MA,Feldman SR, et al.Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S.population,2012.JAMA Dermatol 2015, 151:1081-1086.
19.Wang H,Xu Y,Shi J,et al.Photodynamic therapy in the treatment of basal cell carcinoma:a systematic review and meta-analysis.Photodermatol Photoimmunol Photomed 2015, 31:44-53.
20.McCusker M,Basset-Seguin N,Dummer R,et al.Metastatic basal cell carcinoma:prognosis dependent on anatomic site and spread of disease.Eur J Cancer 2014, 50:774-783.
21.Kaskel P,Lange U,Sander S,et al.Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden,Germany.J Eur Acad Dermatol Venereol 2015, 29:134-142.
22.Sekulic A,Migden MR,Lewis K,et al.Pivotal ERIVANCE basal cell carcinoma (BCC) study:12-month update of efficacy and safety of vismodegib in advanced BCC.J Am Acad Dermatol 2015, 72:1021-1026, e1028.
23.Nguyen-Nielsen M,Wang L,Pedersen L,et al.The incidence of metastatic basal cell carcinoma (mBCC) in Denmark,1997-2010.Eur J Dermatol 2015, 25:463-468.